ArticlePerioperative medicine (London, England)2025
Dexmedetomidine-enhanced chest wall fascial plane blocks in ultra-fast-track minimally invasive heart valve surgery: a randomized controlled trial.
Article in Perioperative medicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundInjury to the sternocostal joint during minimally invasive cardiac surgery frequently results in severe pain, yet there is no established standard for perioperative analgesia. This randomized controlled trial evaluated whether adding 1 μg/kg dexmedetomidine to 0.375% ropivacaine for chest wall fascial plane blocks enhances opioid sparing in ultra-fast-track (UFT) minimally invasive heart valve surgery.
methodsSeventy-six elective patients were randomized (1:1) in a double-blind manner. The control group received 60 mL of 0.375% ropivacaine, while the DEX group was administered 60 mL of 1 μg/kg dexmedetomidine plus 0.375% ropivacaine. The primary outcomes were intraoperative remifentanil use and 24-h postoperative sufentanil consumption, which served as co-primary endpoints to evaluate opioid-sparing effects. Secondary outcomes included 24-h postoperative sufentanil consumption, 24-h oxycodone use, patient-controlled analgesia (PCA) activations, episodes of Visual Analog Scale (VAS) scores ≥ 3 within 48 h, time to recovery of consciousness, time to extubation, duration of intensive care unit (ICU), and hospital stays, and complications.
resultsThe DEX group exhibited significantly reduced intraoperative remifentanil consumption (2.45 ± 0.47 vs. 2.98 ± 0.53 mg, p < 0.001) and 24-h sufentanil use (median with interquartile range (IQR) 57 [54-60] vs. 63 [63-66] μg, p < 0.001). It also demonstrated lower 24-h oxycodone consumption (median [IQR] 5 [0-10] vs. 10 [10-20] mg, p < 0.001), fewer 24-h PCA activations (median [IQR] 3 [2-4] vs. 5 [5-6], p < 0.001), and less frequent VAS ≥ 3 episodes (median [IQR] 3 [2.5-4] vs. 6 [5-6], p < 0.001), alongside shorter lengths of ICU (21.34 ± 3.59 vs. 24.29 ± 4.07 h, p = 0.002) and hospital stays (6.51 ± 1.04 vs. 8.65 ± 1.80 days, p < 0.001). Postoperative complications did not differ significantly between groups, though dexmedetomidine-related hemodynamic effects were not systematically monitored.
conclusionThe administration of 1 μg/kg dexmedetomidine in combination with ropivacaine for chest wall fascial plane blocks reduces opioid requirements and shortens ICU/hospital stays in UFT cardiac surgery, supporting its safety and efficacy, but limitations include the single-center design, fixed dexmedetomidine dosage, and incomplete complication assessment, warranting multicenter validation with standardized safety monitoring.
trial registrationChiCTR2100051182.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.